Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Optimal Management of Bacillus Calmette-Guérin–Refractory

<< Previous

Bullboard Posts

Next >>

Comment by lesflicson Feb 02, 2024 9:20am

168 Views

Post# 35859087

RE:Optimal Management of Bacillus Calmette-Guérin–Refractory

21% CR at 450 days? We are now 37% at.450 days. Why are you posting old data?

Oden6570 wrote:
Photodynamic Therapy

In 2023, interim findings were released, detailing the outcomes of a phase 2 clinical study on intravesical photodynamic therapy for patients with BCG-unresponsive CIS with or without papillary disease (NCT03945162) [42]. The study involved intravesical instillation of the photosensitizer TLD-1433 (0.70 mg/cm2), followed by activation using a 520-nm intravesical laser (Study Device TLC-3200) and consequently delivering a total of 90 J/cm2 of laser light under general anesthesia. Among the 45 enrolled patients, the data showed CR rates of 50% at 90 days, 35% at 360 days, and 21% at 450 days. Eight serious adverse events were identified in the study. The study is currently ongoing, with recruitment in progress, and the estimated completion date is December 2025.